Amdoxovir

Short description: Medication

Amdoxovir

Clinical data
ATC code|

* none

Identifiers

IUPAC name

* [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol

CAS Number|

* 145514-04-1 Y

PubChem CID|

* 124088

ChemSpider|

* 110576 Y

UNII|

* 54I81H0M9C

KEGG|

* D02890 Y

ChEMBL|

* ChEMBL458876 Y

NIAID ChemDB|

* 005431

Chemical and physical data
Formula| C9H12N6O3
Molar mass| 252.234 g·mol−1
3D model (JSmol)|

* Interactive image

SMILES

* n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N

InChI

* InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 Y

* Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N Y

(verify)

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.[1]

Amdoxovir was in advanced Phase II clinical trials around 2010.[2] In 2013, a Phase II trial was terminated[3] and another was withdrawn before it started.[4] No further studies appear to have been done.

## References

1. ↑ "Amdoxovir". AIDSmeds.com. January 13, 2009. http://www.aidsmeds.com/archive/amdoxovir_1591.shtml.
2. ↑ "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther 15 (2): 185–192. 2010. doi:10.3851/IMP1514. PMID 20386073.
3. ↑ Clinical trial number NCT01737359 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
4. ↑ Clinical trial number NCT01738555 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov

* v
* t
* e

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery and development)|

* gp41 (Enfuvirtide (ENF, T-20))
* CCR5 (Maraviroc (MVC)
* Vicriviroc†, Cenicriviroc†, PRO 140†)
* CD4 (Ibalizumab†, UB421§)
* gp120 (Fostemsavir†)

Reverse-transcriptase
inhibitors (RTIs)|

| Nucleoside and
nucleotide (NRTI)|

* Nucleoside analogues/NRTIs: Abacavir (ABC)°#
* Didanosine (ddI)
* Emtricitabine (FTC)°
* Lamivudine (3TC)°#
* Stavudine (d4T)#
* Zidovudine (AZT, ZDV)#
* Amdoxovir†
* Apricitabine†
* Censavudine†
* Elvucitabine†
* Islatravir (EFdA)§
* Racivir†
* Stampidine†
* Zalcitabine (ddC)◊

* Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)°#
* Tenofovir alafenamide (TAF)

|

Non-nucleoside (NNRTI)
(Discovery and development)|

| 1st generation|

* Efavirenz (EFV)°#
* Nevirapine (NVP)#
* Delavirdine (DLV)◊

|

2nd generation|

* diarylpyrimidines
* Etravirine (ETR)
* Rilpivirine (RPV)°
* Doravirine°

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))|

* Dolutegravir (DTG)°
* Elvitegravir (EVG)°
* Raltegravir (RAL)°
* BI 224436†
* Cabotegravir†
* Bictegravir (BIC)†
* MK-2048†

Maturation inhibitors|

* Bevirimat†
* BMS-955176§

Protease Inhibitors (PI)
(Discovery and development)|

| 1st generation|

* Amprenavir (APV)◊
* Fosamprenavir (FPV)
* Indinavir (IDV)◊
* Lopinavir (LPV)
* Nelfinavir (NFV)
* Ritonavir (RTV)#
* Saquinavir (SQV)#

|

2nd generation|

* Atazanavir (ATV)°#
* Darunavir (DRV)°#
* Tipranavir (TPV)

Combined formulations|

* Abacavir/lamivudine°#
* Abacavir/dolutegravir/lamivudine°
* Abacavir/lamivudine/zidovudine
* Atazanavir/cobicistat
* Bictegravir/emtricitabine/tenofovir alafenamide
* Darunavir/cobicistat
* Dolutegravir/lamivudine
* Doravirine/lamivudine/tenofovir disoproxil
* Efavirenz/emtricitabine/tenofovir°#
* Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
* Elvitegravir/cobicistat/emtricitabine/tenofovir°
* Emtricitabine/tenofovir alafenamide
* Emtricitabine/rilpivirine/tenofovir alafenamide
* Emtricitabine/rilpivirine/tenofovir°
* Emtricitabine/tenofovir°#
* Lamivudine/raltegravir
* Lamivudine/zidovudine#
* Lopinavir/ritonavir°#

Pharmacokinetic boosters|

* Cobicistat (c)
* Ritonavir (r)#

Experimental agents|

| Uncoating inhibitors|

* TRIM5alpha (gene)

|

Transcription inhibitors|

* Tat antagonists

Translation inhibitors|

* Trichosanthin

Other|

* Abzyme
* BIT225†
* Calanolide A
* Ceragenin
* Cyanovirin-N
* Diarylpyrimidines
* Epigallocatechin gallate (EGCG)
* Foscarnet
* Fosdevirine†
* Griffithsin
* Hydroxycarbamide
* KP-1461†
* Miltefosine
* Portmanteau inhibitors
* Scytovirin
* Seliciclib†
* Synergistic enhancers
* Tre recombinase
* Zinc finger protein transcription factor

Failed agents|

* Aplaviroc
* Atevirdine
* Brecanavir
* Capravirine
* Dexelvucitabine
* Droxinavir
* Lasinavir
* Emivirine
* Lersivirine
* Lodenosine
* Loviride
* Mozenavir
* Palinavir
* Telinavir

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Amdoxovir. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Amdoxovir&oldid=413399"
*[CID]: Compound ID
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template